Atopic Dermatitis Market Research Report- Global Forecast till 2023

Report / Search Code: MRFR/HC/1079-HCRR  Publish Date: October, 2018

Price
1-user PDF : $ 4450.0  Enterprise PDF : $ 6250.0

Description:

Atopic Dermatitis Market Information: By Type (Hormone, Erythropoietin, Monoclonal Antibodies, and Calcitonin), By Application (Cancer, Blood Disorders, and Chronic Diseases), By End User (Hospitals, Research Centers, Clinics) - Global Forecast till 2023

Market Scenario

Atopic dermatitis is the most common type of eczema, patients who are suffering with this disease have super sensitive skin and a decreased threshold for irritation. Additionally it misguides the immune system which leads to chronic diseases. The prevalence of atopic dermatitis are very common worldwide, that occur more often in infants and children. Atopic dermatitis includes hay fever, food allergies, atopic dermatitis, allergic asthma, and anaphylaxis.

Atopic dermatitis have various patterns depending on the age of patients. It can occur in the knees, inside the elbows, sides of the neck, wrists, ankles, and hands and has the tendency to develop papules which leads to rashes. It is characterized by low quantity of filaggrin protein that allows skin to become dry and reduces its protective abilities. Additionally, the skin is very susceptible to infections, such as staphylococcal and streptococcal bacterial skin infections, warts, herpes simplex, and molluscum contagiosum. The atopic dermatitis market growth is majorly attributed to the increasing prevalence of atopic disorders, decreased quantity of protein called filaggrin in skin. Moreover, rising funding along with government support for research and development fuel the market of atopic dermatitis. Moreover, advancing technology in medical devices is adding fuel to the growth of the market.

According to a report published by the National Center for Biotechnology Information, in 2015, atopic dermatitis was recorded to affect around 20% of infants & children and 3% of adults globally.

A research study published in the National Eczema Association, in 2016, shows that around 9.6 million children under the age of 18years, which is 13% of U.S. population, have atopic dermatitis. Additionally, in 2016, the United States spend around $314 million on health system to treat atopic dermatitis patients.

However, availability of expensive treatment and poor reimbursement policies in the developing regions of the world are some of the factors, which may hamper the market growth during the forecast period.

The global atopic dermatitis market is expected to grow at a CAGR of 8.2% during the forecast period 2017-2023.

Intended Audience

- Pharmaceutical Companies
- Medical Devices Companies
- Research and Development (R&D) Companies
- Government Research Institute
- Medical Research Laboratories
- Academic Medical Institutes and Universities
Figure: Global Atopic dermatitis Market, By Region Market Share, 2016 (%)

Sources: Annual reports, Press release, White paper, Company presentation

Segmentations

The global atopic dermatitis market is segmented on the basis of types, by application, and by end user.

On the basis of the type, it is segmented into hormone, Erythropoietin, Monoclonal antibodies, Interferon, Calcitonin, and others.

On the basis of the application, it is segmented into Cancer, blood disorders, chronic diseases, infectious diseases, and others.

On the basis of end user, it is segmented into hospitals, clinics, and research centers.

Regional Analysis

The Americas dominate the global atopic dermatitis market owing to well-developed technology, increasing patient with low quantity of protein filaggrin, increasing prevalence atopic disorder, high healthcare spending, and increasing government support for research & development. Furthermore, increased R&D activities and the concentration of major companies have fuelled the growth of the market in this region. Rising in the adoption of skin irritants such as soaps, detergents, perfumes, cosmetics and even water may inflame the skin.

Europe holds the second position in the global atopic dermatitis market owing to the government support for research & development and availability of funds for research. This is expected to continue to drive the European market over the forecasted period. For instance, countries like Germany and France are increasing investment in the healthcare domain.

Asia Pacific is the fastest growing atopic dermatitis market owing to the presence of rapidly developing healthcare technology, huge patient population, and high healthcare expenditure. Moreover, increasing demand for new treatment methods in countries like India and South Korea is likely to emerge as the fastest growing market across the globe. Furthermore, increasing demand for quality devices in the healthcare is projected to lead to the use of advanced equipment, which, in turn, will increase the market growth of the atopic dermatitis in the region.

On the other hand, in the Middle East and Africa, blood disorders have become a huge problem due to limited screening, ignorance of diseases, and poor access to treatment.

Key Players

Some of key the players in the market are Astellas Pharma Inc. (Japan), Sanofi S.A. (France), Regeneron Pharmaceuticals, Inc. (U.S.), Valeant Pharmaceuticals International, Inc (Canada), Anacor Pharmaceuticals Inc. (U.S.), Novartis International AG (Switzerland), Bristol-Myers Squibb (U.S.), Meda Pharmaceuticals (U.S.), Pfizer Inc. (U.S.), Galderma S.A. (Switzerland), Allergan Plc. (Republic of Ireland)
Research Methodology

Sources: Annual reports, Press release, White paper, and Company presentation

Contents:

Table of Content

1. Report Prologue

2. Market Introduction
   2.1 Definition
   2.2 Scope of the Study
   2.2.1 Research Objective
   2.2.2 Assumptions
   2.2.3 Limitations

3. Research Methodology
   3.1 Introduction
   3.2 Primary Research
   3.3 Secondary research
   3.4 Market Size Estimation

4. Market Dynamics
   4.1 Drivers
   4.2 Restraints
   4.3 Opportunities
   4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment

5. Market Factor Analysis
5.1 Porters Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis

6. Global Atopic Dermatitis Market, by Type
6.1 Introduction
6.2 Hormone
6.2.1 Market Estimates & Forecast, 2017-2023
6.3 Erythropoietin
6.3.1 Market Estimates & Forecast, 2017-2023
6.4 Monoclonal antibodies
6.4.1 Market Estimates & Forecast, 2017-2023
6.5 Interferon
6.5.1 Market Estimates & Forecast, 2017-2023
6.6 Calcitonin
6.6.1 Market Estimates & Forecast, 2017-2023
6.7 Others
6.7.1 Market Estimates & Forecast, 2017-2023

7. Global Atopic Dermatitis Market, by Application
7.1 Introduction
7.2 Cancer
7.2.1 Market Estimates & Forecast, 2017-2023
7.3 Blood Disorders
7.3.1 Market Estimates & Forecast, 2017-2023
7.4 Chronic Diseases
7.4.1 Market Estimates & Forecast, 2017-2023
7.5 Infectious Diseases
7.5.1 Market Estimates & Forecast, 2017-2023
7.6 Others
7.6.1 Market Estimates & Forecast, 2017-2023

8. Global Atopic Dermatitis Market, by End User
8.1 Introduction
8.2 Hospitals
8.2.1 Market Estimates & Forecast, 2017-2023
8.3 Clinics
8.3.1 Market Estimates & Forecast, 2017-2023
8.4 Research centers
8.4.1 Market Estimates & Forecast, 2017-2023

9. Global Atopic Dermatitis Market, by Region
9.1 Introduction
9.2 Americas
9.2.1 North America
9.2.1.1 U.S.
9.2.1.1 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 U.K
9.3.1.4 Italy
9.3.1.5 Spain
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Republic of Korea
9.4.6 Rest of Asia Pacific
9.5 The Middle East & Africa
9.5.1 United Arab Emirates
9.5.2 Saudi Arabia
9.5.3 Oman
9.5.4 Kuwait
9.5.5 Qatar
9.5.6 Rest of the Middle East & Africa

10 Company Landscape
10.1 Introduction
10.2 Market Share Analysis
10.3 Key Development & Strategies
10.3.1 Key Developments
11 Company Profiles
11.1 Astellas Pharma Inc.
11.1.1 Company Overview
11.1.2 Product Overview
11.1.3 Financials
11.1.4 SWOT Analysis
11.2 Sanofi S.A.
11.2.1 Company Overview
11.2.2 Product Overview
11.2.3 Financial Overview
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.3 Regeneron Pharmaceuticals, Inc.
11.3.1 Company Overview
11.3.2 Product Overview
11.3.3 Financial Overview
11.3.4 Key Development
11.3.5 SWOT Analysis
11.4 Valeant Pharmaceuticals International, Inc
11.4.1 Company Overview
11.4.2 Product/Business Segment Overview
11.4.3 Financial Overview
11.4.4 Key Development
11.4.5 SWOT Analysis
11.5 Anacor Pharmaceuticals Inc.
11.5.1 Company Overview
11.5.2 Product Overview
11.5.3 Financial overview
11.5.4 Key Developments
11.6 Novartis International AG
11.6.1 Company Overview
11.6.2 Product Overview
11.6.3 Financial Overview
11.6.4 Key Developments
11.7 Bristol-Myers Squibb
11.7.1 Overview
11.7.2 Product Overview
11.7.3 Financials
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.8 Others
12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s View Point

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of Pharmaceutical Industry

13 Appendix

LIST OF TABLES

Table 1 Atopic Dermatitis Industry Synopsis, 2017-2023
Table 2 Global Atopic Dermatitis Market Estimates and Forecast, 2017-2023, (USD Million)
Table 3 Global Atopic Dermatitis Market by Region, 2017-2023, (USD Million)
Table 4 Global Atopic Dermatitis Market by Types, 2017-2023, (USD Million)
Table 5 Global Atopic Dermatitis Market by Application, 2017-2023, (USD Million)
Table 6 Global Atopic Dermatitis Market by End Users, 2017-2023, (USD Million)
Table 7 North America Atopic Dermatitis Market by Types, 2017-2023, (USD Million)
Table 8 North America Atopic Dermatitis Market by Application, 2017-2023, (USD Million)
Table 9 North America Atopic Dermatitis Market by End Users, 2017-2023, (USD Million)
Table 10 US Atopic Dermatitis Market by Types, 2017-2023, (USD Million)
Table 11 US Atopic Dermatitis Market by Application, 2017-2023, (USD Million)
Table 12 US Atopic Dermatitis Market by End Users, 2017-2023, (USD Million)
Table 13 Canada Atopic Dermatitis Market by Types, 2017-2023, (USD Million)
Table 14 Canada Atopic Dermatitis Market by Application, 2017-2023, (USD Million)
Table 15 Canada Atopic Dermatitis Market by End Users, 2017-2023, (USD Million)
Table 16 South America Atopic Dermatitis Market by Types, 2017-2023, (USD Million)
Table 17 South America Atopic Dermatitis Market by Application, 2017-2023, (USD Million)
Table 18 South America Atopic Dermatitis Market by End Users, 2017-2023, (USD Million)
Table 19 Europe Atopic Dermatitis Market by Types, 2017-2023, (USD Million)
Table 20 Europe Atopic Dermatitis Market by Application, 2017-2023, (USD Million)
Table 21 Europe Atopic Dermatitis Market by End Users, 2017-2023, (USD Million)
Table 22 Western Europe Atopic Dermatitis Market by Types, 2017-2023, (USD Million)
Table 23 Western Europe Atopic Dermatitis Market by Application, 2017-2023, (USD Million)
Table 24 Western Europe Atopic Dermatitis Market by End Users, 2017-2023, (USD Million)
Table 25 Eastern Europe Atopic Dermatitis Market by Types, 2017-2023, (USD Million)
Table 26 Eastern Europe Atopic Dermatitis Market by Application, 2017-2023, (USD Million)
Table 27 Eastern Europe Atopic Dermatitis Market by End Users, 2017-2023, (USD Million)
Table 28 Asia Pacific Atopic Dermatitis Market by Types, 2017-2023, (USD Million)
Table 29 Asia Pacific Atopic Dermatitis Market by Application, 2017-2023, (USD Million)
Table 30 Asia Pacific Atopic Dermatitis Market by End Users, 2017-2023, (USD Million)
Table 31 Middle East & Africa Atopic Dermatitis Market by Types, 2017-2023, (USD Million)
Table 32 Middle East & Africa Atopic Dermatitis Market by Application, 2017-2023, (USD Million)
Table 33 Middle East & Africa Atopic Dermatitis Market by End Users, 2017-2023, (USD Million)

LIST OF FIGURES

Figure 1 Research Process
Figure 2 Segmentation for Global Atopic Dermatitis Market
Figure 3 Segmentation Market Dynamics for Atopic Dermatitis Market
Figure 4 Global Atopic Dermatitis Market Share, by Type 2016
Figure 5 Global Atopic Dermatitis Market Share, by Application 2016
Figure 6 Global Atopic Dermatitis Market Share, by End Users, 2016
Figure 7 Global Atopic Dermatitis Market Share, by Region, 2016
Figure 8 America Atopic Dermatitis Market Share, by Country, 2016
Figure 9 Europe Atopic Dermatitis Market Share, by Country, 2016
Figure 10 Asia Pacific Atopic Dermatitis Market Share, by Country, 2016
Figure 11 Middle East & Africa Atopic Dermatitis Market Share, by Country, 2016
Figure 12 Global Atopic Dermatitis Market: Company Share Analysis, 2016 (%)
Figure 13 Astellas Pharma Inc.: Key Financials
Figure 14 Astellas Pharma Inc.: Segmental Revenue
Figure 15 Astellas Pharma Inc.: Geographical Revenue
Figure 16 Sanofi S.A.: Key Financials
Figure 17 Sanofi S.A.: Segmental Revenue
Figure 18 Sanofi S.A.: Geographical Revenue
Figure 19 Regeneron Pharmaceuticals, Inc.: Key Financials
Figure 20 Regeneron Pharmaceuticals, Inc.: Segmental Revenue
Figure 21 Regeneron Pharmaceuticals, Inc.: Geographical Revenue
Figure 22 Valeant Pharmaceuticals International, Inc: Key Financials
Figure 23 Valeant Pharmaceuticals International, Inc: Segmental Revenue
Figure 24 Valeant Pharmaceuticals International, Inc: Geographical Revenue
Figure 25 Anacor Pharmaceuticals Inc.: Key Financials
Figure 26 Anacor Pharmaceuticals Inc.: Segmental Revenue
Figure 27 Anacor Pharmaceuticals Inc.: Geographical Revenue
Figure 28 Novartis International AG: Key Financials
Figure 29 Novartis International AG: Segmental Revenue
Figure 30 Novartis International AG: Geographical Revenue
Figure 31 Bristol-Myers Squibb: Key Financials
Figure 32 Bristol-Myers Squibb: Segmental Revenue
Figure 33 Bristol-Myers Squibb: Geographical Revenue